von Willebrand disease: treatment with or without factor VIII?
Konkle
B A
BA
Penn Comprehensive Hemophilia and Thrombosis Program, University of Pennsylvania School of Medicine, Philadelphia, PA, USA. barbara.konkle@uphs.upenn.edu
D003894:Deamino Arginine Vasopressin / Q000627:therapeutic use; D005169:Factor VIII / Q000008:administration & dosage / Q000009:adverse effects / Q000378:metabolism / Q000627:therapeutic use*; D006801:Humans; D013927:Thrombosis / Q000209:etiology; D014842:von Willebrand Diseases / Q000097:blood / Q000188:drug therapy*; D014841:von Willebrand Factor / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*
D014841:von Willebrand Factor; D005169:Factor VIII; D003894:Deamino Arginine Vasopressin